tiprankstipranks
Trending News
More News >
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
US Market
Advertisement

bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

Compare
106 Followers

Top Page

BIAF

bioAffinity Technologies, Inc.

(NASDAQ:BIAF)

Rating:50Neutral
Price Target:
$0.50
▲(42.86%Upside)
bioAffinity Technologies, Inc. faces significant financial challenges with negative profitability and cash flow metrics. Technical analysis offers mixed signals, with short-term bullishness but long-term bearish trends. While recent corporate events show promise with new patents and positive product validation, the Nasdaq non-compliance notice adds risk. The overall score reflects these mixed factors, with financial instability being the most significant concern.
Positive Factors
Growth Potential
CyPath Lung sales were up 276% year-over-year, indicating strong growth potential despite some temporary setbacks.
Market Adoption
The number of physician offices offering the CyPath Lung test increased significantly, indicating growing adoption of the diagnostic test.
Product Success
The initial success of CyPath Lung in Texas has expanded to several other states through referrals and word-of-mouth, with expected momentum to continue through 2025.
Negative Factors
Capital Constraints
The company's capital constraints remain a concern, impacting the ability to operate profitably without raising additional funds.
Funding Challenges
BIAF needs to raise additional capital, as current cash reserves and burn rate indicate potential funding challenges.
Revenue Guidance
The company introduced 2025 revenue guidance significantly below prior estimates, leading to a downgrade of the stock to Hold.

bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company DescriptionbioAffinity Technologies, Inc. (BIAF) is a biotechnology company focused on developing non-invasive diagnostic tests and targeted therapies to detect and treat early-stage cancer. The company operates within the healthcare and biotechnology sectors, leveraging its expertise in cellular biology to create innovative solutions that address unmet medical needs. Its core products include diagnostic assays and therapeutic agents designed to improve patient outcomes by enabling early detection and treatment of cancer.
How the Company Makes MoneybioAffinity Technologies, Inc. generates revenue primarily through the commercialization of its diagnostic and therapeutic products. The company sells its products to healthcare providers, laboratories, and research institutions. Additionally, bioAffinity may enter into licensing agreements and partnerships with other biotechnology and pharmaceutical companies to co-develop or distribute its products, providing additional revenue streams. Research grants and funding from governmental and non-governmental organizations might also contribute to the company's earnings by supporting its research and development activities.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary
bioAffinity Technologies, Inc. faces significant financial challenges with negative profitability and cash flow metrics. Despite some potential in revenue growth, high leverage and negative profit margins highlight financial instability.
Income Statement
30
Negative
The income statement shows a volatile revenue growth with a significant increase from 2022 to 2023, but a decline in 2024. The company is struggling with negative profit margins, including gross profit, net profit, and EBITDA margins. The EBIT margin remains negative, reflecting operating inefficiencies and a challenging path to profitability.
Balance Sheet
40
Negative
The balance sheet indicates a high debt-to-equity ratio, suggesting substantial leverage, which could pose financial risks. However, there is a slight improvement in equity ratio over time. The company has been able to maintain positive stockholders' equity in recent periods after a negative balance in previous years.
Cash Flow
35
Negative
Cash flow analysis reveals consistent negative free cash flows, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, reflecting cash burn. However, free cash flow to net income improved slightly in recent periods, showing potential for future cash efficiency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.36M2.53M4.80K0.000.00
Gross Profit3.38M791.62K4.34K-4.82K-22.24K
EBITDA-8.33M-7.63M-5.61M-2.20M-6.86M
Net Income-9.04M-7.94M-8.15M-6.33M-7.27M
Balance Sheet
Total Assets6.51M8.22M12.18M1.45M145.60K
Cash, Cash Equivalents and Short-Term Investments1.11M2.82M11.41M1.36M83.11K
Total Debt1.50M1.58M251.75K11.36M10.01M
Total Liabilities3.91M3.37M1.14M17.24M15.22M
Stockholders Equity2.60M4.86M11.04M-15.79M-15.07M
Cash Flow
Free Cash Flow-7.34M-6.06M-4.29M-2.05M-2.21M
Operating Cash Flow-7.26M-6.04M-4.07M-2.05M-2.21M
Investing Cash Flow-79.08K-2.21M-219.99K0.00-2.89K
Financing Cash Flow5.63M-344.98K14.34M3.33M1.72M

bioAffinity Technologies, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.35
Price Trends
50DMA
0.29
Positive
100DMA
0.36
Negative
200DMA
0.73
Negative
Market Momentum
MACD
0.02
Negative
RSI
56.85
Neutral
STOCH
73.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Positive. The current price of 0.35 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.29, and below the 200-day MA of 0.73, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 73.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIAF.

bioAffinity Technologies, Inc. Risk Analysis

bioAffinity Technologies, Inc. disclosed 83 risk factors in its most recent earnings report. bioAffinity Technologies, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

bioAffinity Technologies, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$21.49M-25.29%26.67%44.02%
61
Neutral
$13.13M-126.34%3.87%91.76%
55
Neutral
$7.59M-809.29%
50
Neutral
$9.88M-290.85%78.40%22.41%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
43
Neutral
$12.62M77.20%-4.02%-6.60%
41
Neutral
$11.64M-127.82%-24.04%84.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BIAF
bioAffinity Technologies, Inc.
0.35
-2.36
-87.08%
TRIB
Trinity Biotech
0.70
-2.16
-75.52%
PRPO
Precipio
14.70
9.16
165.34%
BNGO
BioNano Genomics
3.38
-34.24
-91.02%
INBS
Intelligent Bio Solutions
1.90
0.40
26.67%
MYNZ
Mainz Biomed B.V.
2.04
-11.39
-84.81%

bioAffinity Technologies, Inc. Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
bioAffinity’s CyPath® Lung Test Identifies Missed Tumor
Positive
Jul 23, 2025

On July 23, 2025, bioAffinity Technologies announced a case study where their CyPath® Lung test successfully identified a Stage 1A neuroendocrine tumor in a patient’s lung, which was missed by other diagnostic tools. This highlights the test’s importance as an adjunct to traditional imaging and diagnostic methods, offering clarity in cases where other tools are inconclusive, thus potentially improving patient outcomes through early detection and treatment.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
bioAffinity Technologies Secures Canadian Patent for Lung Cancer Detection
Positive
Jul 22, 2025

On July 22, 2025, bioAffinity Technologies announced that it received a notification of allowance from the Canadian Patent Office for a patent application related to methods of predicting lung cancer using flow cytometry. This patent, titled ‘System and Method for Determining Lung Health,’ protects the use of specific antibodies and porphyrin TCPP to label cell populations in sputum and utilize flow cytometry to detect lung cancer cells. The patent strengthens the company’s international protection for its diagnostic platform, particularly its flagship test, CyPath® Lung. This development is significant as lung cancer is the leading cause of cancer deaths in Canada, and the patent is expected to expand bioAffinity’s market presence in the region, enhancing shareholder value and highlighting the company’s focus on early cancer detection.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
bioAffinity Technologies Secures Chinese Patent for Lung Cancer Detection
Positive
Jul 15, 2025

On July 15, 2025, bioAffinity Technologies announced it received a notification of allowance from the China National Intellectual Property Administration for a patent related to predicting lung cancer likelihood using flow cytometry. This patent positions the company to expand its proprietary diagnostic platform in China, a significant market with a high prevalence of smokers and lung cancer cases. The patent protects the use of specific antibodies and porphyrin TCPP in labeling cell populations in sputum to detect lung cancer cells, enhancing the company’s global patent portfolio and supporting its strategy to build long-term shareholder value through innovation and early cancer detection.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
bioAffinity Receives Nasdaq Non-Compliance Notice
Negative
May 30, 2025

On May 27, 2025, bioAffinity Technologies, Inc. received a notice from Nasdaq indicating non-compliance with the stockholders’ equity requirement of $2,500,000, as their equity was reported at $1,439,404 as of March 31, 2025. The company plans to submit a compliance plan by July 11, 2025, to address this issue and maintain its listing on the Nasdaq Capital Market. The notification does not immediately affect the company’s listing, and they are exploring options to regain compliance, although acceptance of the plan by Nasdaq is not guaranteed. This notice is separate from a previous deficiency related to the minimum bid price requirement.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Private Placements and Financing
bioAffinity Technologies Enters Sales Agreement with WallachBeth
Positive
May 27, 2025

On May 22, 2025, bioAffinity Technologies, Inc. entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC to facilitate the sale of its common stock through an ‘at the market offering’ program. This agreement allows the company to sell shares directly on the Nasdaq Capital Market or other trading platforms, with WallachBeth acting as the sales agent. The agreement provides flexibility in terms of the number of shares sold and the timing, while also allowing for termination by either party under certain conditions. The arrangement is expected to enhance the company’s financial flexibility and market presence.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Shareholder Meetings
bioAffinity Technologies Sets 2025 Annual Meeting Date
Neutral
May 19, 2025

bioAffinity Technologies, Inc. has announced plans for its 2025 Annual Meeting of Stockholders, which will take place on July 25, 2025. The company has set the record date for determining stockholders entitled to vote at the meeting as May 29, 2025. Due to the meeting being scheduled more than 30 days after the previous year’s meeting, revised deadlines for stockholder proposals have been provided. Proposals under Rule 14a-8 must be submitted by May 26, 2025, while notices for director nominations must comply with Rule 14a-19 by May 29, 2025.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Private Placements and Financing
bioAffinity Technologies Completes $3.2M Public Offering
Neutral
May 8, 2025

On May 7, 2025, bioAffinity Technologies, Inc. completed a public offering of common stock and warrants, raising approximately $3.2 million in gross proceeds. The company plans to use the funds for working capital and general corporate purposes. The offering included agreements that restrict the issuance of additional shares for a specified period, which may impact the company’s market activities and shareholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025